NIR Photodynamic Destruction of PDAC and HNSCC Nodules Using Triple-Receptor-Targeted Photoimmuno-Nanoconjugates: Targeting Heterogeneity in Cancer

Receptor heterogeneity in cancer is a major limitation of molecular targeting for cancer therapeutics. Single-receptor-targeted treatment exerts selection pressures that result in treatment escape for low-receptor-expressing tumor subpopulations. To overcome this potential for heterogeneity-driven r...

Full description

Bibliographic Details
Main Authors: Shazia Bano, Girgis Obaid, Joseph W. R. Swain, Marina Yamada, Brian W. Pogue, Kenneth Wang, Tayyaba Hasan
Format: Article
Language:English
Published: MDPI AG 2020-07-01
Series:Journal of Clinical Medicine
Subjects:
Online Access:https://www.mdpi.com/2077-0383/9/8/2390
id doaj-5b096276765d425ba4a267fc34c3d23b
record_format Article
spelling doaj-5b096276765d425ba4a267fc34c3d23b2020-11-25T02:36:36ZengMDPI AGJournal of Clinical Medicine2077-03832020-07-0192390239010.3390/jcm9082390NIR Photodynamic Destruction of PDAC and HNSCC Nodules Using Triple-Receptor-Targeted Photoimmuno-Nanoconjugates: Targeting Heterogeneity in CancerShazia Bano0Girgis Obaid1Joseph W. R. Swain2Marina Yamada3Brian W. Pogue4Kenneth Wang5Tayyaba Hasan6Wellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USAWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USAWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USAWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USAThayer School of Engineering, Dartmouth College, Hanover, NH 03755, USADivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USAWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USAReceptor heterogeneity in cancer is a major limitation of molecular targeting for cancer therapeutics. Single-receptor-targeted treatment exerts selection pressures that result in treatment escape for low-receptor-expressing tumor subpopulations. To overcome this potential for heterogeneity-driven resistance to molecular targeted photodynamic therapy (PDT), we present for the first time a triple-receptor-targeted photoimmuno-nanoconjugate (TR-PIN) platform. TR-PIN functionalization with cetuximab, holo-transferrin, and trastuzumab conferred specificity for epidermal growth factor receptor (EGFR), transferrin receptor (TfR), and human epidermal growth factor receptor 2 (HER-2), respectively. The TR-PINs exhibited up to a 24-fold improvement in cancer cell binding compared with EGFR-specific cetuximab-targeted PINs (Cet-PINs) in low-EGFR-expressing cell lines. Photodestruction using TR-PINs was significantly higher than the monotargeted Cet-PINs in heterocellular 3D in vitro models of heterogeneous pancreatic ductal adenocarcinoma (PDAC; MIA PaCa-2 cells) and heterogeneous head and neck squamous cell carcinoma (HNSCC, SCC9 cells) containing low-EGFR-expressing T47D (high TfR) or SKOV-3 (high HER-2) cells. Through their capacity for multiple tumor target recognition, TR-PINs can serve as a unique and amenable platform for the effective photodynamic eradication of diverse tumor subpopulations in heterogeneous cancers to mitigate escape for more complete and durable treatment responses.https://www.mdpi.com/2077-0383/9/8/2390intratumoral heterogeneitybiomarkersmultiple receptor-targetingcetuximabholo-transferrintrastuzumab
collection DOAJ
language English
format Article
sources DOAJ
author Shazia Bano
Girgis Obaid
Joseph W. R. Swain
Marina Yamada
Brian W. Pogue
Kenneth Wang
Tayyaba Hasan
spellingShingle Shazia Bano
Girgis Obaid
Joseph W. R. Swain
Marina Yamada
Brian W. Pogue
Kenneth Wang
Tayyaba Hasan
NIR Photodynamic Destruction of PDAC and HNSCC Nodules Using Triple-Receptor-Targeted Photoimmuno-Nanoconjugates: Targeting Heterogeneity in Cancer
Journal of Clinical Medicine
intratumoral heterogeneity
biomarkers
multiple receptor-targeting
cetuximab
holo-transferrin
trastuzumab
author_facet Shazia Bano
Girgis Obaid
Joseph W. R. Swain
Marina Yamada
Brian W. Pogue
Kenneth Wang
Tayyaba Hasan
author_sort Shazia Bano
title NIR Photodynamic Destruction of PDAC and HNSCC Nodules Using Triple-Receptor-Targeted Photoimmuno-Nanoconjugates: Targeting Heterogeneity in Cancer
title_short NIR Photodynamic Destruction of PDAC and HNSCC Nodules Using Triple-Receptor-Targeted Photoimmuno-Nanoconjugates: Targeting Heterogeneity in Cancer
title_full NIR Photodynamic Destruction of PDAC and HNSCC Nodules Using Triple-Receptor-Targeted Photoimmuno-Nanoconjugates: Targeting Heterogeneity in Cancer
title_fullStr NIR Photodynamic Destruction of PDAC and HNSCC Nodules Using Triple-Receptor-Targeted Photoimmuno-Nanoconjugates: Targeting Heterogeneity in Cancer
title_full_unstemmed NIR Photodynamic Destruction of PDAC and HNSCC Nodules Using Triple-Receptor-Targeted Photoimmuno-Nanoconjugates: Targeting Heterogeneity in Cancer
title_sort nir photodynamic destruction of pdac and hnscc nodules using triple-receptor-targeted photoimmuno-nanoconjugates: targeting heterogeneity in cancer
publisher MDPI AG
series Journal of Clinical Medicine
issn 2077-0383
publishDate 2020-07-01
description Receptor heterogeneity in cancer is a major limitation of molecular targeting for cancer therapeutics. Single-receptor-targeted treatment exerts selection pressures that result in treatment escape for low-receptor-expressing tumor subpopulations. To overcome this potential for heterogeneity-driven resistance to molecular targeted photodynamic therapy (PDT), we present for the first time a triple-receptor-targeted photoimmuno-nanoconjugate (TR-PIN) platform. TR-PIN functionalization with cetuximab, holo-transferrin, and trastuzumab conferred specificity for epidermal growth factor receptor (EGFR), transferrin receptor (TfR), and human epidermal growth factor receptor 2 (HER-2), respectively. The TR-PINs exhibited up to a 24-fold improvement in cancer cell binding compared with EGFR-specific cetuximab-targeted PINs (Cet-PINs) in low-EGFR-expressing cell lines. Photodestruction using TR-PINs was significantly higher than the monotargeted Cet-PINs in heterocellular 3D in vitro models of heterogeneous pancreatic ductal adenocarcinoma (PDAC; MIA PaCa-2 cells) and heterogeneous head and neck squamous cell carcinoma (HNSCC, SCC9 cells) containing low-EGFR-expressing T47D (high TfR) or SKOV-3 (high HER-2) cells. Through their capacity for multiple tumor target recognition, TR-PINs can serve as a unique and amenable platform for the effective photodynamic eradication of diverse tumor subpopulations in heterogeneous cancers to mitigate escape for more complete and durable treatment responses.
topic intratumoral heterogeneity
biomarkers
multiple receptor-targeting
cetuximab
holo-transferrin
trastuzumab
url https://www.mdpi.com/2077-0383/9/8/2390
work_keys_str_mv AT shaziabano nirphotodynamicdestructionofpdacandhnsccnodulesusingtriplereceptortargetedphotoimmunonanoconjugatestargetingheterogeneityincancer
AT girgisobaid nirphotodynamicdestructionofpdacandhnsccnodulesusingtriplereceptortargetedphotoimmunonanoconjugatestargetingheterogeneityincancer
AT josephwrswain nirphotodynamicdestructionofpdacandhnsccnodulesusingtriplereceptortargetedphotoimmunonanoconjugatestargetingheterogeneityincancer
AT marinayamada nirphotodynamicdestructionofpdacandhnsccnodulesusingtriplereceptortargetedphotoimmunonanoconjugatestargetingheterogeneityincancer
AT brianwpogue nirphotodynamicdestructionofpdacandhnsccnodulesusingtriplereceptortargetedphotoimmunonanoconjugatestargetingheterogeneityincancer
AT kennethwang nirphotodynamicdestructionofpdacandhnsccnodulesusingtriplereceptortargetedphotoimmunonanoconjugatestargetingheterogeneityincancer
AT tayyabahasan nirphotodynamicdestructionofpdacandhnsccnodulesusingtriplereceptortargetedphotoimmunonanoconjugatestargetingheterogeneityincancer
_version_ 1724799142708903936